UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000013795
Receipt No. R000016103
Scientific Title Phase II study of Bendamustine-Rituximab therapy for CD20-positive untreated and advanced follicular lymphoma with poor response to R-CHOP therapy
Date of disclosure of the study information 2014/04/24
Last modified on 2020/11/07 02:07:06

No. Disposal Last modified on Item of update
1 Insert 2014/04/23 18:19:37
2 Update 2014/04/28 13:13:56 Acronym
3 Update 2014/04/28 13:15:21 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
4 Update 2016/10/24 10:57:42 Name of primary sponsor
Organization
5 Update 2017/04/25 09:19:32 Recruitment status
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
6 Update 2020/10/27 14:53:41 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
TEL
Email

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
7 Update 2020/10/27 14:54:28 Number of participants that the trial has enrolled
8 Update 2020/10/27 14:55:47 Date of IRB
Last follow-up date
Date of closure to data entry
Date trial data considered complete
9 Update 2020/11/07 02:07:06 Basic objectives2
Basic objectives -Others
Basic objectives -Others
Key secondary outcomes
Key secondary outcomes


Contact us.